Fennec Pharmaceuticals Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated August 22, 2022, reports the completion of the first closing of a financing transaction by Fennec Pharmaceuticals Inc. (FENC) with Petrichor Opportunities Fund I LP. The company is a clinical-stage biopharmaceutical firm focused on developing novel therapies for rare diseases.
Key Financial Metrics and Transaction Details
- Financing Structure: Senior secured floating rate convertible notes with a total potential issuance of up to $45,000,000.
- First Closing Amount: $5,000,000 funded on August 19, 2022.
- Conversion Price (First Closing): $8.11 per share (20% premium to 5-day VWAP prior to August 1, 2022).
- Interest Rate: Greater of US Prime Rate or 3.5%, plus a 4.5% margin. For the first 24 months, 3.5% of interest is paid-in-kind (PIK).
- Maturity Date: August 1, 2027.
- Commitment Fee: 2.0% of the Notes, partially paid via warrants (55,498 shares) and partially in cash or warrants.
- Warrant Terms: Exercisable at $8.11 per share with a five-year term.
Material Changes and Future Tranches
The filing details a multi-tranche structure contingent on regulatory milestones:
- Second Closing: $20,000,000 tranche to be funded upon FDA approval of the company's drug candidate, PEDMARK, and satisfaction of other conditions.
- Subsequent Closings: Up to an additional $20,000,000 available before December 31, 2023, in $10,000,000 tranches upon mutual agreement.
- Conversion Price Cap: Conversion prices for future tranches are capped at 150% of the Initial Conversion Price ($8.11).
Outlook, Risks, and Covenants
Management has entered into significant covenants restricting future indebtedness, liens, dividends, and asset transfers while the Notes are outstanding. The company must maintain a minimum amount of unrestricted cash. The Notes are redeemable by the company after August 1, 2025, subject to redemption premiums (110% prior to August 2026; 107.5% thereafter). Risks include the failure to obtain FDA approval for PEDMARK, which would prevent the funding of the $20,000,000 Second Closing tranche, and potential dilution upon conversion of notes and warrants.
Investor Verification Checklist
- Verify the current status of the FDA review for PEDMARK to assess the likelihood of the $20,000,000 Second Closing.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Note terms (Exhibit 4.1) for specific default triggers and redemption mechanics.
- Monitor the company's unrestricted cash balance to ensure compliance with minimum liquidity covenants.
- Check for the filing of the registration statement required within 105 days of closing to ensure shares underlying the notes and warrants can be registered.